Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

638
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
638
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

7.2K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

TET1 Inhibition Promotes Therapeutic Sensitivity in TP53-Mutant GBM by Influencing Genome Fragility and Altering TAMs Biology.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

The WYZ-1 mouse glioblastoma stem cell model: A novel preclinical tool for tumor and therapy studies.

Cancer letters·2026
Same author

ANK1 and EPB41 Variants and the Risk of Steroid-Induced Osteonecrosis.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same author

Highly dynamic dural sinuses support meningeal immunity.

Nature·2026
Same author

Galectin-9 in human trophoblast cells: Implications for maternal-fetal immune balance and pregnancy complications.

Life sciences·2026
Same author

Expanding the clinical tumor phenotype of the EPAS1-asssociated tumor syndrome.

The Journal of clinical endocrinology and metabolism·2026

Related Experiment Video

Updated: Aug 22, 2025

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.3K

Targeting PP2A for cancer therapeutic modulation.

Halle Ronk1, Jared S Rosenblum1, Timothy Kung1

  • 1Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Cancer Biology & Medicine
|November 7, 2022
PubMed
Summary

Protein phosphatase 2A (PP2A) inhibition, using the agent LB100, shows promise in cancer therapy. LB100 acts as a chemo- and radio-sensitizing agent, with ongoing clinical trials exploring its efficacy.

Keywords:
Chemo-sensitizationLB100PP2A inhibitionclinical trialscolorectal cancerglioblastomaimmunotherapyprotein phosphatase 2Aradio-sensitizationsmall molecule inhibitor

More Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.8K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.4K

Related Experiment Videos

Last Updated: Aug 22, 2025

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.3K
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.8K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.4K

Area of Science:

  • Molecular Biology
  • Oncology
  • Pharmacology

Background:

  • Protein phosphatases, particularly Protein Phosphatase 2A (PP2A), are crucial negative regulators in cellular signaling pathways.
  • PP2A is the primary serine/threonine phosphatase in the nervous system and plays roles in cell cycle, apoptosis, and DNA repair.
  • While traditionally viewed as a tumor suppressor, PP2A inhibition is emerging as a viable cancer therapeutic strategy.

Purpose of the Study:

  • To review the development and therapeutic potential of LB100, a novel PP2A inhibitor.
  • To discuss the role of PP2A in cancer biology and its inhibition as a treatment modality.
  • To highlight recent advancements in targeting PP2A for cancer immunotherapy.

Main Methods:

  • Literature review of LB100 development and preclinical/clinical studies.
  • Analysis of PP2A's function in cancer signaling and regulation.
  • Exploration of current research on PP2A inhibition in cancer treatment and immunotherapy.

Main Results:

  • LB100 demonstrates potential as a chemo- and radio-sensitizing agent.
  • Multiple clinical trials are investigating LB100 as an adjuvant therapy for various cancers, including lung cancer, myelodysplastic syndrome, and glioblastoma.
  • Preclinical data supports the paradoxical therapeutic benefit of PP2A inhibition in cancer.

Conclusions:

  • PP2A inhibition represents a promising therapeutic avenue in oncology.
  • LB100 is a key agent in exploring PP2A-targeted cancer therapies.
  • Further research into PP2A inhibition, especially in combination with immunotherapy, is warranted.